Patent 12123035

Assignment history

Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.

Active provider: Google · gemini-2.5-flash

Ownership chain (5)

Asserters network →

Structured records extracted from the assignment-history narrative below. Each entity links to its full ownership-network profile.

  1. 2022-12-23 · reel 059905/0149 · ASSIGNMENT OF ASSIGNORS INTEREST

    HALOZYME THERAPEUTICS, INC.HALOZYME, INC.

    Correspondent: MCDONALD, MICHAEL R.

    internal reorg

  2. 2022-12-23 · reel 059905/0147 · ASSIGNMENT OF ASSIGNORS INTEREST

    CONNOR, ROBERT JAMESHALOZYME THERAPEUTICS, INC.

    Correspondent: MCDONALD, MICHAEL R.

    transfer from inventor to operating company

  3. 2022-12-23 · reel 059905/0145 · ASSIGNMENT OF ASSIGNORS INTEREST

    SHEPARD, H. MICHAELHALOZYME, INC.

    Correspondent: MCDONALD, MICHAEL R.

    transfer from inventor to operating company

  4. 2022-12-23 · reel 059905/0143 · ASSIGNMENT OF ASSIGNORS INTEREST

    WEI, GEHALOZYME THERAPEUTICS, INC.

    Correspondent: MCDONALD, MICHAEL R.

    transfer from inventor to operating company

  5. 2022-12-23 · reel 059905/0141 · ASSIGNMENT OF ASSIGNORS INTEREST

    ZHAO, QIPINGHALOZYME THERAPEUTICS, INC.

    Correspondent: MCDONALD, MICHAEL R.

    transfer from inventor to operating company

Assignment history

Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.

✓ Generated

Inventors

  • Ge Wei (Halozyme Inc.)
  • H. Michael Shepard (Halozyme Inc.)
  • Qiping Zhao (Halozyme Inc.)
  • Robert James Connor (Halozyme Inc.)

It is generally presumed that inventions made by employees within the scope of their employment are assigned to the employer, especially if an assignment agreement is in place. Halozyme Inc. is the original assignee, indicating the inventors were employed there at the time of filing.

Original assignee

The original assignee is Halozyme Inc.. Halozyme is a publicly traded biotechnology company headquartered in San Diego, California. Their primary line of business is developing and commercializing drug-device combination products using their proprietary ENHANZE® drug delivery technology, which utilizes a recombinant human hyaluronidase enzyme (rHuPH20) to enable subcutaneous administration of injectable biologics. They have an FDA-approved product called Hylenex® recombinant, which is a hyaluronidase injection. Halozyme is currently operating and actively engaged in collaborations and licensing agreements with major pharmaceutical companies.

Assignment timeline

  • 2022-12-23 / recorded 2022-12-23 — Reel 059905/0149
    • Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST
    • Assignor: HALOZYME THERAPEUTICS, INC.
    • Assignee: HALOZYME, INC.
    • Correspondent: MCDONALD, MICHAEL R.; HALOZYME, INC.
    • Context: Internal reorg (transfer from Halozyme Therapeutics, Inc. to Halozyme, Inc.)
  • 2022-12-23 / recorded 2022-12-23 — Reel 059905/0147
    • Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST
    • Assignor: CONNOR, ROBERT JAMES
    • Assignee: HALOZYME THERAPEUTICS, INC.
    • Correspondent: MCDONALD, MICHAEL R.; HALOZYME, INC. (This correspondent also appears on reel 059905/0149 for this patent.)
    • Context: Transfer from inventor to operating company
  • 2022-12-23 / recorded 2022-12-23 — Reel 059905/0145
    • Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST
    • Assignor: SHEPARD, H. MICHAEL
    • Assignee: HALOZYME, INC.
    • Correspondent: MCDONALD, MICHAEL R.; HALOZYME, INC. (This correspondent also appears on reel 059905/0149 and 059905/0147 for this patent.)
    • Context: Transfer from inventor to operating company
  • 2022-12-23 / recorded 2022-12-23 — Reel 059905/0143
    • Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST
    • Assignor: WEI, GE
    • Assignee: HALOZYME THERAPEUTICS, INC.
    • Correspondent: MCDONALD, MICHAEL R.; HALOZYME, INC. (This correspondent also appears on reel 059905/0149, 059905/0147, and 059905/0145 for this patent.)
    • Context: Transfer from inventor to operating company
  • 2022-12-23 / recorded 2022-12-23 — Reel 059905/0141
    • Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST
    • Assignor: ZHAO, QIPING
    • Assignee: HALOZYME THERAPEUTICS, INC.
    • Correspondent: MCDONALD, MICHAEL R.; HALOZYME, INC. (This correspondent also appears on reel 059905/0149, 059905/0147, 059905/0145, and 059905/0143 for this patent.)
    • Context: Transfer from inventor to operating company

Timeline diagram

timeline
    title Ownership of US 12123035
    2022 : Inventors to Halozyme Therapeutics Inc
         : Halozyme Therapeutics Inc to Halozyme Inc
    2024 : Issued to Halozyme Inc

NPE / troll-pattern signals

  1. Shell-entity transfer — not present. All transfers are between individuals and "Halozyme Therapeutics, Inc." or "Halozyme, Inc.", which are known operating companies.
  2. Known asserter in the chain — not present. Halozyme Inc. is an operating biotechnology company.
  3. Repeat correspondent across the chain — present. Michael R. McDonald of Halozyme, Inc. is listed as the correspondent on all recorded assignments (Reel 059905/0149, 059905/0147, 059905/0145, 059905/0143, and 059905/0141), indicating these were likely internal or routine transfers for the operating company.
  4. Cascading transfers — not present. All recorded assignments occurred on the same date (2022-12-23) and appear to be part of an initial setup or internal reorganization, transferring inventor rights to the company.
  5. Pre-litigation transfer — unclear. While the assignment date (2022-12-23) predates the patent issuance (2024-10-22), there is no information about litigation in the provided data to assess if it was a pre-litigation transfer.
  6. Bankruptcy fire-sale — not present. Halozyme Inc. is an active, publicly traded company with strong financial performance.
  7. Privateering — not present. The patent remains with the operating company, Halozyme Inc.
  8. Defensive aggregator (anti-NPE) — not present. The patent is owned by Halozyme Inc.

Verdict

Operating-company assertion. The assignment records clearly show transfers from the individual inventors to Halozyme Therapeutics, Inc., and then to Halozyme, Inc., all of which are a single operating entity. Halozyme Inc. is a biotechnology company that develops and commercializes products related to the claimed invention, indicating an intent for commercial use rather than assertion-only. The repeated correspondent on all assignments further supports that these were internal company actions.

USPTO Assignment Center: https://assignmentcenter.uspto.gov/

Generated 6/25/2026, 6:45:41 AM